https://orcid.org/0000-0002-3782-6645
References
- Ahren B, Schmitz O. 2004. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res. 36(11/12):867–876.
- Bai H, Lu J, Cheng X, Liu L, Zhang W, Wei Y, Wang Y, Liu J, Ding J, Yu Q, et al. 2020. Development and validation of an ultrasensitive LC-MS/MS method for the quantification of cetagliptin in human plasma and its application in a microdose clinical trial. Biomed Chromatogr. 35(3):e4994.
- Bian Y, Zhang H, Ma S, Jiao Y, Yan P, Liu X, Ma S, Xiong Y, Gu Z, Yu Z, et al. 2021. Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects. Br J Clin Pharmacol. 87(1):93–105.
- Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. 2010. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 38(4):667–678.
- Deacon CF. 2004. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 53(9):2181–2189.
- Deacon CF. 2011. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 13(1):7–18.
- DeFronzo RA. 1988. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 37(6):667–687.
- Drucker DJ. 2002. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 122(2):531–544.
- Gorrell MD. 2005. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond)). 108(4):277–292.
- He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, et al. 2009. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 37(3):536–544.
- Kieffer TJ, Habener JF. 1999. The glucagon-like peptides. Endocr Rev. 20(6):876–913.
- Lu J, Tian X, Tang D, Zhou X, Xu Z, Ding Wang JT, Yu Q, Ding J. 2021. In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers. Xenobiotica. 51(10):1122–1131.
- Ministry of Health labour and Welfare. 2001. Guidance for Industry. Clinical Pharmacokinetic Studies of Pharmaceuticals. Available from: http://www.nihs.go.jp/phar/pdf/ClPkEng011122.pdf.
- Nakamaru Y, Hayashi Y, Ikegawa R, Kinoshita S, Perez Madera B, Gunput D, Kawaguchi A, Davies M, Mair S, Yamazaki H, et al. 2014. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica. 44(3):242–253.
- Penner N, Klunk LJ, Prakash C. 2009. Human radio labeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos. 30(4):185–203.
- Rajput R. 2009. Dipeptidyl peptidase-IV inhibitors: a new drug in the therapeutic armamentarium for treatment of type 2 diabetes mellitus. JIACM. 10(3):128–133.
- Shaffer CL, Gunduz M, Thornburgh BA, Fate GD. 2006. Using a tritiated compound to elucidate its preclinical metabolic and excretory pathways in vivo: exploring tritium exchange risk. Drug Metab Dispos. 34(9):1615–1623.
- US Food and Drug Administration 2018. Guidance for industry. Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. Available from: https://www.fda.gov/media/70837/download.
- US Food and Drug Administration. 2020. Guidance for industry. Safety testing of drug metabolites guidance for industry. Available from: https://www.fda.gov/media/72279/download.
- Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, et al. 2007. Metabolism and excretion of the dipeptidyl peptidase4 Inhibitor [14C] sitagliptin in humans. Drug Metab Dispos. 35(4):533–538.